Madrigal Pharmaceuticals (MDGL) to Release Earnings on Thursday

Madrigal Pharmaceuticals (NASDAQ:MDGL) is expected to announce its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $310.3580 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 19, 2026 at 8:00 AM ET.

Madrigal Pharmaceuticals Price Performance

Shares of NASDAQ MDGL opened at $481.00 on Thursday. The company has a current ratio of 3.44, a quick ratio of 3.26 and a debt-to-equity ratio of 0.54. The firm has a market cap of $10.92 billion, a P/E ratio of -36.97, a price-to-earnings-growth ratio of 6.80 and a beta of -1.01. The business’s 50 day moving average is $536.16 and its 200-day moving average is $474.48. Madrigal Pharmaceuticals has a 1-year low of $265.00 and a 1-year high of $615.00.

Analysts Set New Price Targets

Several research firms recently weighed in on MDGL. UBS Group set a $900.00 target price on Madrigal Pharmaceuticals in a report on Friday, December 19th. Wolfe Research set a $579.00 price objective on Madrigal Pharmaceuticals in a research note on Tuesday, January 6th. Truist Financial lifted their target price on Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, November 19th. Barclays started coverage on shares of Madrigal Pharmaceuticals in a report on Tuesday, January 27th. They issued an “overweight” rating and a $964.00 target price for the company. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $571.00 price target on shares of Madrigal Pharmaceuticals in a research note on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Madrigal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $654.73.

Insider Activity

In other news, Director Rebecca Taub sold 18,650 shares of the company’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $552.15, for a total value of $10,297,597.50. Following the completion of the sale, the director owned 461,044 shares in the company, valued at $254,565,444.60. This represents a 3.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO William John Sibold sold 2,400 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $575.34, for a total transaction of $1,380,816.00. Following the transaction, the chief executive officer owned 150,074 shares in the company, valued at approximately $86,343,575.16. This trade represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 101,495 shares of company stock valued at $54,568,691. 21.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP bought a new position in Madrigal Pharmaceuticals during the third quarter valued at $39,000. Johnson Financial Group Inc. purchased a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter valued at $50,000. Kestra Investment Management LLC bought a new position in shares of Madrigal Pharmaceuticals during the 2nd quarter worth $85,000. Coldstream Capital Management Inc. bought a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter worth $235,000. Finally, Quantitative Investment Management LLC purchased a new stake in Madrigal Pharmaceuticals in the 3rd quarter worth about $260,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.